NASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis $16.75 -0.03 (-0.18%) (As of 10:12 AM ET) Add Compare Share Share Today's Range$16.50▼$16.9750-Day Range$16.31▼$29.3552-Week Range$7.64▼$30.19Volume31,907 shsAverage Volume694,180 shsMarket Capitalization$965.30 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cullinan Therapeutics alerts: Email Address Cullinan Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside91.0% Upside$32.00 Price TargetShort InterestBearish10.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 3 Articles This WeekInsider TradingSelling Shares$1.63 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.02) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector513th out of 896 stocksBiological Products, Except Diagnostic Industry78th out of 152 stocks 4.5 Analyst's Opinion Consensus RatingCullinan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCullinan Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cullinan Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.28% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Cullinan Therapeutics has recently increased by 4.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEM. Previous Next 2.6 News and Social Media Coverage News SentimentCullinan Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cullinan Therapeutics this week, compared to 2 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,628,060.00 in company stock.Percentage Held by InsidersOnly 6.07% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cullinan Therapeutics are expected to decrease in the coming year, from ($3.02) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Therapeutics has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cullinan Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin Analytics50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?To see this July stock warning for yourself – 100% free – click here. About Cullinan Therapeutics Stock (NASDAQ:CGEM)Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More CGEM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEM Stock News HeadlinesJuly 4 at 1:55 AM | americanbankingnews.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $32.00 Average Target Price from BrokeragesJune 28, 2024 | americanbankingnews.comCullinan Therapeutics (NASDAQ:CGEM) Shares Down 4% July 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?June 9, 2024 | seekingalpha.comChecking Into Cullinan TherapeuticsJune 1, 2024 | globenewswire.comCullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibMay 24, 2024 | globenewswire.comCullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitMay 23, 2024 | globenewswire.comCullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024May 19, 2024 | uk.investing.comCullinan Oncology stock target trimmed, maintains Buy ratingJuly 5, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend Issues July Stock WarningJuly is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks – including NVDA – stumbling?May 16, 2024 | finanznachrichten.deCullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cullinan Management Ahead of Key ASCO Presentation and Strong FinancialsMay 16, 2024 | markets.businessinsider.comBuy Rating on Cullinan Management: Promising Pipeline and Strategic Pivot to AutoimmunityMay 16, 2024 | investorplace.comCGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024May 15, 2024 | globenewswire.comCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comInsider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...May 1, 2024 | markets.businessinsider.comBuy Rating Justified: Cullinan Management’s Promising TCE Therapy Paves the Way for Market DominanceMay 1, 2024 | msn.comStifel Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy RecommendationApril 29, 2024 | globenewswire.comCullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerApril 24, 2024 | finance.yahoo.comWhy Is Cullinan Therapeutics Stock Trading Higher On Wednesday?April 24, 2024 | globenewswire.comCullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024April 17, 2024 | finanznachrichten.deCullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesApril 16, 2024 | markets.businessinsider.comBuy Recommendation: Cullinan Management’s Strategic Position in Autoimmune Disease Market with Promising CLN-978 TherapyApril 16, 2024 | bizjournals.comCullinan rebrands with $280M private offering, pivot away from cancerApril 16, 2024 | finance.yahoo.comCullinan changes name, pivots to autoimmune diseaseApril 16, 2024 | markets.businessinsider.comCullinan To Expand Into Autoimmune Diseases, Privately Places $280 Mln; Stock Up In Pre-MarketApril 16, 2024 | markets.businessinsider.comCullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via EquityApril 16, 2024 | marketwatch.comCullinan Oncology Shares Jump 21% on Planned Autoimmune Diseases Expansion, Private PlacementSee More Headlines Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/05/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CGEM CUSIPN/A CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees85Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$40.00 Low Stock Price Target$26.00 Potential Upside/Downside+90.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.65% Return on Assets-27.14% Debt Debt-to-Equity RatioN/A Current Ratio20.33 Quick Ratio20.33 Sales & Book Value Annual Sales$18.94 million Price / Sales51.06 Cash FlowN/A Price / Cash FlowN/A Book Value$10.61 per share Price / Book1.58Miscellaneous Outstanding Shares57,630,000Free Float54,136,000Market Cap$967.03 million OptionableOptionable Beta-0.12 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Nadim Ahmed (Age 56)President, CEO & Director Comp: $1.16MDr. Jeffrey Jones M.B.A. (Age 53)M.D., M.P.H., Chief Medical Officer Comp: $780.32kDr. Patrick A. Baeuerle Ph.D. (Age 66)Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board Comp: $763.73kMs. Mary Kay Fenton (Age 60)Chief Financial Officer Dr. Jennifer Michaelson Ph.D. (Age 57)Chief Scientific Officer Ms. Jacquelyn L. Sumer J.D. (Age 46)Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Ms. Rose WeldonSenior Vice President of CommunicationsMr. Steve AndreChief Human Resources OfficerDr. Corinne Savill Ph.D. (Age 65)Chief Business Officer Mr. Kevin A. JohnstonChief Technical Operations OfficerMore ExecutivesKey CompetitorsXencorNASDAQ:XNCRMacroGenicsNASDAQ:MGNXBlack Diamond TherapeuticsNASDAQ:BDTXSpectrum PharmaceuticalsNASDAQ:SPPIInnate PharmaNASDAQ:IPHAView All CompetitorsInsiders & InstitutionsKennedy Capital Management LLCSold 75,778 shares on 5/16/2024Ownership: 0.196%California State Teachers Retirement SystemSold 1,449 shares on 5/16/2024Ownership: 0.055%Affinity Asset Advisors LLCSold 41,412 shares on 5/15/2024Ownership: 0.600%Price T Rowe Associates Inc. MDBought 820 shares on 5/15/2024Ownership: 0.053%American International Group Inc.Sold 1,223,822 shares on 5/14/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions CGEM Stock Analysis - Frequently Asked Questions Should I buy or sell Cullinan Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGEM shares. View CGEM analyst ratings or view top-rated stocks. What is Cullinan Therapeutics' stock price target for 2024? 6 brokerages have issued twelve-month price objectives for Cullinan Therapeutics' stock. Their CGEM share price targets range from $26.00 to $40.00. On average, they anticipate the company's stock price to reach $32.00 in the next year. This suggests a possible upside of 91.0% from the stock's current price. View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts. How have CGEM shares performed in 2024? Cullinan Therapeutics' stock was trading at $10.19 at the start of the year. Since then, CGEM shares have increased by 64.4% and is now trading at $16.75. View the best growth stocks for 2024 here. When is Cullinan Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CGEM earnings forecast. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) released its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.86) earnings per share for the quarter, topping analysts' consensus estimates of ($0.90) by $0.04. What ETFs hold Cullinan Therapeutics' stock? ETFs with the largest weight of Cullinan Therapeutics (NASDAQ:CGEM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and First Trust Dow Jones Select Microcap Index Fund (FDM).Tema Oncology ETF (CANC). When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $149 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGEM) was last updated on 7/5/2024 by MarketBeat.com Staff From Our Partners50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEM Stock Alerts